Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Sues To Block 'Unprecedented' California Price Reporting Law

Executive Summary

Ban on WAC price increases violates Commerce Clause and reporting requirement violates First Amendment, PhRMA contends; complaint says state officials have not clarified whether law is retroactive.

You may also be interested in...



Mallinckrodt Must Publicize Price Increases In Wake Of DOJ Settlement On Medicaid Rebates

Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.

Minnesota's Free Insulin Law Has 'Staggering' Implications, PhRMA Says

PhRMA sues to block implementation of the law, saying it could allow states to compel manufacturers to dispense other medications without compensation.

States Take Center Stage In Tackling Rx Drug Pricing

Dozen drug pricing transparency bills enacted into law over past two years impose different requirements on manufacturers, with a few honing in on PBMs; interactive graphic details these and other pharma-related laws.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS122134

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel